Prevail Therapeutics

NEW YORK, NY · Founded 2017 · Biotech · Acquired

AAV-based gene therapy vectors for treating Parkinson's disease and Gaucher disease caused by GBA1 mutations

Claim this profile

Follows are private to you and power your alerts

Updated · prevailtherapeutics.com

Sector
Biotech
Headquarters
NEW YORK, NY
Founded
2017
Latest Form D
$57M, Mar 2018
Total capital
$57M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$57M
1 Form D · last Mar 2018
103 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
15
25 pending · first 2020
Rank in peer group#112 of 1449

Capital timeline

2018FEDERAL ↑EQUITY ↓Cumulative $57M1st Form D$57M
2018FEDERAL ↑EQUITY ↓Cumulative $57M1st Form D$57M

Latest events

  • Private capital raisedForm D · SEC · 1st filing$57M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#112 · top 8%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • ASA ABELIOVICHResearcherExecutive Officer, DirectorLinked by 3 patents
  • CARL GORDONDirectorNamed in SEC Form D filings
  • MONA ASHIYADirectorNamed in SEC Form D filings
  • PETER THOMPSONDirectorNamed in SEC Form D filings

What it has protected

USPTO · 15 granted of 40
Show all 40 patent records
  • Recombinant Adeno-associated Virus Compositions And Methods For Producing SameSep 8, 2026 · US 12,729,385Granted
  • Gene Therapies For Lysosomal DisordersAug 27, 2026 · Application 19465370Pending
  • Gene Therapies For Lysosomal DisordersJul 23, 2026 · Application 19418288Pending
  • Gene Therapies For Lysosomal DisordersJun 18, 2026 · Application 19465813Pending
  • Gene Therapies For Lysosomal DisordersMar 10, 2026 · US 12,570,963Granted
  • Gene Therapies For Lysosomal DisordersMar 10, 2026 · US 12,571,002Granted
  • Gene Therapies For Lysosomal DisordersJan 6, 2026 · US 12,516,298Granted
  • Gene Therapy For Neurodegenerative DisordersJan 9, 2025 · Application 18743624Pending
  • Gene Therapy For Neurodegenerative DisordersJul 30, 2024 · US 12,049,626Granted
  • Gene Therapies For Lysosomal DisordersJun 4, 2024 · US 11,999,974Granted
  • Gene Therapies For Lysosomal DisordersMay 28, 2024 · US 11,993,790Granted
  • Gene Therapies For Lysosomal DisordersApr 18, 2024 · Application 18392002Pending
  • Modulation Of Aav-based Gene ExpressionMar 28, 2024 · Application 18273845Pending
  • Gene Therapies For Lysosomal DisordersFeb 20, 2024 · US 11,903,985Granted
  • Assay For Measuring Potency Of Gene Therapy Drug ProductFeb 8, 2024 · Application 18031494Pending
  • Gene Therapies For Neurodegenerative DiseaseDec 21, 2023 · Application 18038247Pending
  • Gene Therapies For Lysosomal DisordersNov 7, 2023 · US 11,807,849Granted
  • Gene Therapies For Neurodegenerative DisordersNov 2, 2023 · Application 18041199Pending
  • Gene Therapies For Lysosomal DisordersOct 31, 2023 · US 11,802,294Granted
  • Gene Therapies For Lysosomal DisordersOct 5, 2023 · Application 18020575Pending
  • Aav Vectors Encoding Parkin And Uses ThereofSep 28, 2023 · Application 18019357Pending
  • Gene Therapies For Lysosomal DisordersMay 30, 2023 · US 11,661,585Granted
  • Gene Therapies For Lysosomal DisordersMay 23, 2023 · US 11,655,460Granted
  • Compositions And Methods For Treatment Of Friedreich's AtaxiaJul 7, 2022 · Application 17434318Pending
  • Gene Therapies For Lysosomal DisordersJul 7, 2022 · Application 17601984Pending
  • Recombinant Adeno-associated Virus Compositions And Methods For Producing SameApr 21, 2022 · Application 17502979Pending
  • Gene Therapies For Neurodegenerative DiseaseJan 13, 2022 · Application 17297492Pending
  • Gene Therapies For Neurodegenerative DiseasesAug 26, 2021 · Application 16758077Pending
  • Gene Therapies For Lysosomal DisordersJul 13, 2021 · US 11,060,113Granted
  • Gene Therapies For Lysosomal DisordersNov 17, 2020 · US 10,837,028Granted
  • Gene Therapies For Neurodegenerative DiseasesSep 10, 2020 · Application 16857311Pending
  • Gene Therapies For Lysosomal DisordersJun 23, 2020 · US 10,689,625Granted
  • Aav Vectors Encoding Parkin And Uses ThereofApplication 63060353Pending
  • Gene Therapies For Lysosomal DisordersApplication PCTUS2020027658Pending
  • Gene Therapies For Neurodegenerative DiseaseApplication PCTUS2021060731Pending
  • Gene Therapies For Lysosomal DisordersApplication PCTUS2020027788Pending
  • Modulation Of Aav-based ExpressionApplication PCTUS2022013476Pending
  • Gene Therapies For Lysosomal DisordersApplication PCTUS2020027764Pending
  • Compositions And Methods For Treatment Of Friedreich's AtaxiaApplication PCTUS2023078373Pending
  • Gene Therapies For Lysosomal DisordersApplication 62990246Pending

Press

1 article · matched on company name

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .